14 épisodes

Interviews with pharmaceutical innovation leaders and authors. Hosted by Mike Rea, IDEA CEO
www.ideapharma.com @ideapharma

IDEA Collider IDEA Pharma

    • Science de la vie

Interviews with pharmaceutical innovation leaders and authors. Hosted by Mike Rea, IDEA CEO
www.ideapharma.com @ideapharma

    IDEA Collider | Melinda Richter

    IDEA Collider | Melinda Richter

    Melinda Richter
    Global Head of JLABS, Johnson & Johnson Innovation

    On cultures of innovation at the world's largest pharma company, its Innovation group, and the 600+ companies within the JLABS ecosystem - the richest ecosystem in the pharma industry.
    Covering subjects such as diversity, patient-centricity, humanity, intuition, this episode shows why believing in innovation is about more than just the numbers

    • 50 min
    IDEA Collider | Pharma Book Club | Clifton Leaf

    IDEA Collider | Pharma Book Club | Clifton Leaf

    In an archive recording, from 2015, the author of one of the best pharma-related books of the past decade, Clifton Leaf, gives us an insight into The Truth In Small Doses, Why We're Losing the War on Cancer-and How to Win It. (In this case, archive means that we thought we had lost the file, and then found it in a place we didn't expect!)
    Clifton, now Editor In Chief at Fortune Magazine, remains one of the most interesting voices in healthcare

    • 49 min
    IDEA Collider | Jack Scannell

    IDEA Collider | Jack Scannell

    Jack is one of the most interesting minds on the subject of decision quality within pharma and the 'decline' in productivity. This interview focuses on Jack's publications and thoughts around the models we use, and how we could improve decision making in early phase.

    • 57 min
    IDEA Collider | Pharma Book Club | Matt Ridley

    IDEA Collider | Pharma Book Club | Matt Ridley

    Discussion of the new Matt Ridley book, How Innovation Works, published in May 2020. http://www.mattridley.co.uk
    Matt Ridley's books have sold over a million copies, been translated into 31 languages and won several awards. His books include The Red Queen, The Origins of Virtue, Genome, Nature via Nurture, Francis Crick, The Rational Optimist and The Evolution of Everything.

    His TED talk "When Ideas Have Sex" has been viewed more than two million times.

    He writes a weekly column in The Times (London) and writes regularly for the Wall Street Journal.

    As Viscount Ridley, he was elected to the House of Lords in February 2013. He served on the science and technology select committee 2014-2017.

    With BA and DPhil degrees from Oxford University, Matt Ridley worked for the Economist for nine years as science editor, Washington correspondent and American editor, before becoming a self-employed writer and businessman.

    • 31 min
    IDEA Collider | In conversation with Amrit Chaudhuri

    IDEA Collider | In conversation with Amrit Chaudhuri

    Amrit Chaudhuri is CEO of SmartLabs, an on-demand, pharma-grade research environment to accelerate scientific discovery and therapeutic commercialization.

    Amrit is a recognized leader and entrepreneur in life sciences. He is the founder of Advanced Peptides, a specialty contract research organization focused on peptide chemistry.

    Amrit holds numerous patents, has successfully created five companies, and has been involved in many FDA clinical trials. In 2017, INC Magazine named Amrit one of the "Top 20 Healthcare Innovators and Entrepreneurs".

    • 51 min
    IDEA Collider | Vinayak K Prasad | Pharma Book Club

    IDEA Collider | Vinayak K Prasad | Pharma Book Club

    Interview with Vinayak K. Prasad, author of Malignant: How Bad Policy and Bad Evidence Harm People with Cancer

    An essential listen for anyone involved in cancer R&D. Vinay is one of the more interesting voices on Twitter (@VPrasadMDMPH), and the book presents a wonderful exploration of what's right with oncology R&D and what's wrong. The interview reveals how positively he sees the opportunity to refocus on what matters to oncologists, and more importantly, to patients. The book is published in late April 2020, so I'd recommend a pre-order to ensure you get it on the day of release.

    From the book's website (http://www.vinayakkprasad.com/books)
    Each week, people read about new and exciting cancer drugs. Some of these drugs are truly transformative, offering major improvements in how long patients live or how they feel—but what is often missing from the popular narrative is that, far too often, these new drugs have marginal or minimal benefits. Some are even harmful. In Malignant, hematologist-oncologist Dr. Vinayak K. Prasad writes about the many sobering examples of how patients are too often failed by cancer policy and by how oncology is practiced. Throughout this work, Prasad illuminates deceptive practices which:

    • promote novel cancer therapies long before credible data are available to support such treatment

    • exaggerate the potential benefits of new therapies, many of which cost thousands and in some cases hundreds of thousands of dollars

    Prasad then critiques the financial conflicts of interest that pervade the oncology field, the pharmaceutical industry, and the US Food and Drug administration.

    This is a book about how the actions of human beings—our policies, our standards of evidence, and our drug regulation—incentivize the pursuit of marginal or unproven therapies at lofty and unsustainable prices. Prasad takes us through how cancer trials are conducted, how drugs come to market, and how pricing decisions are made, asking how we can ensure that more cancer drugs deliver both greater benefit and a lower price. Ultimately, Prasad says,

    • more cancer clinical trials should measure outcomes that actually matter to people with cancer;

    • patients on those trials should look more like actual global citizens;

    • we need drug regulators to raise, not perpetually lower, the bar for approval; and

    • we need unbiased patient advocates and experts.

    This well-written, opinionated, and engaging book explains what we can do differently to make serious and sustained progress against cancer—and how we can avoid repeating the policy and practice mistakes of the past.

    • 56 min

Classement des podcasts dans Science de la vie